The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
About 90 percent of people fully inoculated by the Pfizer-BioNTech vaccine are well protected from variants of the novel ...
Investing.com - German biotech company CureVac sued Moderna (NASDAQ:MRNA) in Delaware federal court on Friday, alleging that Moderna’s COVID-19 vaccine Spikevax infringed CureVac patents related to ...
Pfizer (PFE) and BioNTech (BNTX) have halted recruitment for a large U.S.-based clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50-64 years, citing challenges in ...
Add Yahoo as a preferred source to see more of our stories on Google. Pfizer Inc. signage is seen on July 22, 2020 in New York City. (Jeenah Moon via Getty Images) This story was originally published ...
BioNTech SE (NASDAQ:BNTX) is included among the 10 Best Global Stocks to Buy According to Wall Street Analysts. BioNTech SE ...
LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...
Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results